Pidilite Industries — Annual Report FY2026
Quality Scores
AI Summary
Pidilite Industries is the undisputed leader in India's consumer glue and construction chemicals market, commanded by iconic brands like Fevicol, Dr. Fixit, and M-Seal. Over the last decade, the company has transformed from a single-brand adhesive maker into a multi-category powerhouse with over 6,500 products. Financial performance is characterized by steady 11% revenue and 12% profit CAGRs, supported by high return ratios and a debt-free balance sheet. The company dominates the Consumer & Bazaar segment (80% revenue share) through a massive distribution network and deep brand equity.…
Key Changes
Over the last decade, Pidilite has evolved from being an adhesive manufacturer to a multi-category powerhouse in construction chemicals and DIY products. The firm has successfully executed a 'String of Pearls' acquisition strategy, acquiring brands like Araldite and CIPY to dominate niche high-performance segments. There is a visible shift towards premiumization, particularly in the Dr. Fixit and Roff ranges, which capitalize on the maturing Indian construction sector. The company has also aggressively expanded its 'Bazaar' reach into rural markets, increasing its distribution footprint to over 4 million outlets. Digitization of the supply chain and welder/carpenter loyalty programs (like Fevicryl and Fevicol Champions' Club) have created deep professional moats. Most recently, the entry…
Management Commentary
The Parekh family and professional management led by Bharat Puri (MD) have demonstrated exceptional vision and execution. Management has successfully navigated several macro headwinds, including GST implementation and volatile VAM pricing. Transparency in communication is high, evidenced by regular analyst meets and detailed investor presentations. The management focus remains on 'Domestic Volume Growth' and expanding the reach into rural markets (Rurban). There is a clear emphasis on digital transformation and ESG initiatives in recent annual reports. Executive compensation is well-aligned with company performance and shows no signs of excessive extraction. The leadership has successfully institutionalized the brand-building process beyond Fevicol.
Financial Highlights
Pidilite exhibits robust financial health with consistent top-line growth and resilient operating margins. Sales have grown from INR 4,844 Cr in 2015 to INR 12,383 Cr in 2024, showing the scale-up capability. Operating Profit Margins (OPM) generally oscillate between 17% and 24%, reflecting the ability to pass on raw material price hikes to consumers over time. The company has maintained an average ROE of 23% and ROCE of 30% over the last decade, indicating high capital efficiency. Net profit growth has outpaced sales in recent years, reaching INR 1,747 Cr in FY24. The equity capital remains largely stable, showing no major dilution. Recent quarterly performance indicates a positive trend in margins as input costs stabilize.
Major Opportunities
- Dominant market share (Fevicol/Dr.Fixit)
- Strong pricing power
- Consistent 10Y RoE > 20%
Major Risks
- High sensitivity to Vinyl Acetate Monomer (VAM) prices
- Expensive valuations (P/E ~60x)
- Growth slowdown in B2B segment
Unlock the full report
Full 20+ sections, charts, AI chat with the report, and PDF export are available with Premium.